Picture loading failed.

Anti-IL23A therapeutic antibody (Pre-made Brazikumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-079-1mg 1mg 3090
GMP-Bios-ab-079-10mg 10mg 21890
GMP-Bios-ab-079-100mg 100mg 148000
GMP-Bios-ab-079-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-IL23A therapeutic antibody (Pre-made Brazikumab biosimilar,Whole mAb)
INN Name Brazikumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
Conditions Approvedna
Conditions ActiveCrohn's disease;Ulcerative colitis
Conditions DiscontinuedPsoriasis
Development Techna